| Drug ID: | Drug136 |
|---|---|
| Drug Name: | Filgotinib |
| CID: | 49831257 |
| DrugBank ID: | DB14845 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT03201445, , NCT06865417, , NCT02914522, , NCT02914535, , NCT05479058, , NCT05817942, , NCT03046056, , NCT03077412, , NCT02914561, , NCT02048618 |
| Molecular Formula: | C21H23N5O3S |
| Molecular Weight: | 425.5 g/mol |
| Isomeric SMILES: | C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5 |
| Synonyms: | Filgotinib; 1206101-20-3; GLPG0634; 1206161-97-8; GLPG-0634; N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide; Filgotinib (GLPG0634); N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide; N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide; Filgotinib(GLPG0634) |
| Phase 0: | 0 |
| Phase 1: | 6 |
| Phase 2: | 14 |
| Phase 3: | 17 |
| Phase 4: | 7 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1090 | 49831257 | Filgotinib | 3716 | JAK1 | Homo sapiens (human) | Inhibitor | |
| dt1091 | 49831257 | Filgotinib | 3717 | JAK2 | Homo sapiens (human) | 24417533 | Inhibition |
| dt1092 | 49831257 | Filgotinib | 3717 | JAK2 | Homo sapiens (human) | 24006460 | Inhibition |
| dt1093 | 49831257 | Filgotinib | 3716 | JAK1 | Homo sapiens (human) | 24417533 | Inhibition |
| dt1094 | 49831257 | Filgotinib | 3716 | JAK1 | Homo sapiens (human) | 24006460 | Inhibition |
| dt1095 | 49831257 | Filgotinib | 3718 | JAK3 | Homo sapiens (human) | 24006460 | Inhibition |
| dt1096 | 49831257 | Filgotinib | 2049 | EPHB3 | Homo sapiens (human) | Inhibitor | |
| dt1097 | 49831257 | Filgotinib | 3716 | JAK1 | Homo sapiens (human) | 24818516 | Tyrosine-protein kinase JAK1 inhibitor |
| dt1098 | 49831257 | Filgotinib | 3717 | JAK2 | Homo sapiens (human) | 33741556 | Tyrosine-protein kinase JAK2 inhibitor |
| dt1099 | 49831257 | Filgotinib | 7297 | TYK2 | Homo sapiens (human) | 33741556 | Tyrosine-protein kinase TYK2 inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05653791 | Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis | NULL | UNKNOWN | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Ulcerative Colitis | DIAGNOSTIC_TEST: Intestinal ultrasound | Details |
| NCT05479058 | A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission | PHASE3 | TERMINATED | Galapagos NV | Ulcerative Colitis | DRUG: Filgotinib|DRUG: Placebo | Details |
| NCT06964113 | A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice | PHASE4 | RECRUITING | Eisai Korea Inc. | Ulcerative Colitis | DRUG: Filgotinib Maleate | Details |
| NCT03201445 | Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease | PHASE2 | TERMINATED | Galapagos NV | Inflammatory Bowel Disease | DRUG: Filgotinib|DRUG: Placebo|DRUG: Standard of … | Details |
| NCT06865417 | A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis | PHASE3 | RECRUITING | Alfasigma S.p.A. | Ulcerative Colitis | DRUG: Filgotinib | Details |
| NCT03077412 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease | PHASE2 | COMPLETED | Gilead Sciences | Fistulizing Crohn's Disease | DRUG: Filgotinib|DRUG: Placebo to match filgotinib | Details |
| NCT03046056 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) | PHASE2 | COMPLETED | Gilead Sciences | Small Bowel Crohn's Disease | DRUG: Filgotinib|DRUG: Placebo to match filgotinib | Details |
| NCT02914600 | Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease | PHASE3 | TERMINATED | Galapagos NV | Crohn's Disease | DRUG: Filgotinib|DRUG: Placebo | Details |
| NCT02914561 | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease | PHASE3 | COMPLETED | Galapagos NV | Crohn's Disease | DRUG: Filgotinib|OTHER: Placebo | Details |
| NCT02914535 | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | PHASE3 | ACTIVE_NOT_RECRUITING | Alfasigma S.p.A. | Ulcerative Colitis | DRUG: Filgotinib|DRUG: Placebo | Details |
| NCT02914522 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | Gilead Sciences | Ulcerative Colitis | DRUG: Filgotinib|DRUG: PTM filgotinib | Details |
| CTRI/2018/07/014719 | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to.Evaluate the Testicular Safety of Filgotinib in Adult Males with.Moderately to Severely Active Inflammatory Bowel Disease. | PHASE2 | Not Recruiting | Gilead Sciences Inc | Health Condition 1: K509- Crohns disease, unspeci… | Intervention1: Filgotinib 200mg oral tablet: Filg… | Details |
| NCT06246123 | A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants | NULL | RECRUITING | Eisai Korea Inc. | Arthritis, Rheumatoid|Colitis, Ulcerative | OTHER: Non-interventional | Details |
| NCT05817942 | Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) | NULL | ACTIVE_NOT_RECRUITING | Alfasigma S.p.A. | Ulcerative Colitis | DRUG: Filgotinib | Details |
| NCT02048618 | Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease | PHASE2 | COMPLETED | Galapagos NV | Crohn's Disease | DRUG: GLPG0634|DRUG: Placebo | Details |
| NCT05687474 | Baby Detect : Genomic Newborn Screening | NULL | COMPLETED | Centre Hospitalier Universitaire de Liege | Congenital Adrenal Hyperplasia|Familial Hyperinsu… | None | Details |
| NCT05643534 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | PHASE3 | RECRUITING | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… | Details |
| NCT05633706 | Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis | NULL | RECRUITING | Nimble Science Ltd. | Irritable Bowel Syndrome|Crohn Disease|Celiac Dis… | DEVICE: fluid biopsy capsule | Details |
| NCT07168434 | Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome | PHASE3 | RECRUITING | Biocodex | IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… | DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… | Details |
| NCT05602116 | ASC - Autism Study | PHASE1 | COMPLETED | Cell to Cure ApS | Autism Spectrum Disorder|Gastrointestinal Dysfunc… | DRUG: Adipose tissue derived mesenchymal stromal/… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Clinical remission in patients with moderate-to-severe Crohn's disease treated …
PMID: 27988142
Year: 2017
Relationship Type:
Treatment
Score: 7.3
BACKGROUND: Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examine…
Ulcerative colitis disease severity affects the speed of symptom relief under f…
PMID: 40583491
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND/AIMS: Filgotinib is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for the treatment of ulcerative colitis (UC). This…
Factors associated with response to filgotinib and the prognostic power of faec…
PMID: 40379541
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Patients with moderately to severely active ulcerative colitis have distinct filgotinib response trajectories. AIMS: Evaluate factors ass…
Major adverse cardiovascular, thromboembolic and malignancy events in the filgo…
PMID: 40037922
Year: 2025
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthr…
Real-world assessment of effectiveness and safety of filgotinib in 286 patients…
PMID: 39917051
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre…
Continuous Treatment with Tofacitinib but Not Filgotinib Is Effective in Non-Re…
PMID: 39797304
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Background: Few studies have compared the efficacy and safety of Janus kinase (JAK) inhibitors in patients with ulcerative colitis (UC). We compared …
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circ…
PMID: 39656830
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: We utilized patient samples from the large, phase 2b/3 SELECTION trial to identify circulating biomarkers of ulcerative colitis (UC) and …
Filgotinib induction-study baseline characteristics of patients with ulcerative…
PMID: 39026439
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND/AIMS: Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristic…
Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ul…
PMID: 38066679
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment of ulcerative colitis in S…
The role of filgotinib in ulcerative colitis and Crohn's disease
PMID: 38009327
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcera…
Integrated safety analysis of filgotinib for ulcerative colitis: Results from S…
PMID: 37718932
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Filgotinib 200 mg (FIL200) is an approved treatment for adults with moderately to severely active ulcerative colitis (UC). AIM: To report…
Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of …
PMID: 37155235
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Filgotinib was approved in Germany for treating patients with moderate to severe active ulcerative colitis in November 2021. It represent…
Effects of filgotinib on semen parameters and sex hormones in male patients wit…
PMID: 37137672
Year: 2023
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: The phase 2 MANTA and MANTA-RAy studies aimed to determine if the oral Janus kinase 1 preferential inhibitor filgotinib affects semen par…
Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy i…
PMID: 36928705
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: The efficacy of new therapies for ulcerative colitis [UC] is usually influenced by previous biologic use. These post hoc analyse…
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Dis…
PMID: 36756874
Year: 2023
Relationship Type:
Clinical Trial
Score: 6.5
BACKGROUND AND AIMS: Ulcerative colitis [UC] impacts patients' health-related quality of life [HRQoL]. We assessed HRQoL and an exploratory patient-l…
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Ev…
PMID: 36725788
Year: 2023
Relationship Type:
Treatment
Score: 6.5
The National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgotinib (Jyseleca((R))), as part of the Single Techn…
Filgotinib for moderately to severely active ulcerative colitis
PMID: 36278878
Year: 2022
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). …
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated …
PMID: 36113491
Year: 2023
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment. We used the par…
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active U…
PMID: 36006011
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-spari…
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's diseas…
PMID: 35762272
Year: 2023
Relationship Type:
Clinical Trial
Score: 6.5
The validity and relevance of histologic disease activity in Crohn's disease (CD) is unclear, owing to disconnects with endoscopic pathology. Here, w…